Geoffrey Y. Ku, MD, provides perspective on the CheckMate-577 clinical study presented at ESMO 2020

A study found worse esophagectomy outcomes at private equity–acquired centers; however, one expert warns against broad conclusions about private equity involvement.

The FDA approved subcutaneous nivolumab across all adult solid tumor indications for nivolumab.

ODAC determined that the risks outweigh the benefits for frontline checkpoint inhibitors in gastric and esophageal cancers with low PD-L1 expression.

Chemotherapy before and after surgery improves survival for patients with locally advanced esophageal adenocarcinoma over neoadjuvant chemoradiotherapy.

The FDA approved tislelizumab in adult patients with unresectable or metastatic esophageal squamous cell carcinoma who have previously received chemotherapy.

The FDA approved first-line pembro plus chemo in adults with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.

Zolbetuximab (IMAB362) plus chemotherapy improved survival in CLDN18.2+ gastric cancer, and an FDA application for the drug is expected by the end of the year.

Neoadjuvant therapy with a trio of chemotherapy drugs led to longer life for patients with advanced esophageal squamous cell cancer.

At ASCO GI 2021 trials like IMbrave150 advanced the conversation on combined therapies, other studies like FIGHT pointed to the growing influence of FGFR-targeted therapies, and the power of molecular technology in guiding treatment was on full display. Data at this year's virtual symposium proved the point that treating GI cancers is anything but one-size-fits-all.